NCT02182622View on ClinicalTrials.gov

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

DRUG

Prednisone

DRUG

LDE225

Trial Locations (1)

07601

John Theurer Cancer @ HackensackUMC, Hackensack

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Martin Gutierrez

OTHER

NCT02182622 - LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | Biotech Hunter | Biotech Hunter